Ken Griffin Janux Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,600 shares of JANX stock, worth $563,992. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,600
Previous 5,600
142.86%
Holding current value
$563,992
Previous $60,000
753.33%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding JANX
# of Institutions
123Shares Held
25.3MCall Options Held
92KPut Options Held
161K-
Orbimed Advisors LLC San Diego, CA4.28MShares$177 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$121 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$115 Million0.2% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$81.5 Million0.04% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$70.2 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.73B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...